Laura B. Goddard

Array ( [id] => 16514207 [patent_doc_number] => 20200393465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => MARKERS, METHODS AND SYSTEMS FOR IDENTIFYING CELL POPULATIONS, DIAGNOSING, MONITORING, PREDICTING AND TREATING CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/899476 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17775079 [patent_doc_number] => 20220241428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/618349 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18384533 [patent_doc_number] => 11655305 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Treatment of metastatic breast cancer [patent_app_type] => utility [patent_app_number] => 16/890176 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 37744 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16890176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720474 [patent_doc_number] => 20220213194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/610897 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656092 [patent_doc_number] => 20210052728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 15/930798 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466800 [patent_doc_number] => 20200368337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => SHARED NEOANTIGENS [patent_app_type] => utility [patent_app_number] => 16/859252 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221327 [patent_doc_number] => 20200246443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => THERAPEUTIC CANCER VACCINE TARGETED TO HAAH (ASPARTYL-[ASPARAGINYL]-BETA-HYDROXYLASE) [patent_app_type] => utility [patent_app_number] => 16/856319 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226921 [patent_doc_number] => 12006555 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments [patent_app_type] => utility [patent_app_number] => 16/854654 [patent_app_country] => US [patent_app_date] => 2020-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 29 [patent_no_of_words] => 43310 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 276 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16854654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336766 [patent_doc_number] => 10787713 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Mutations of the PIK3CA gene in human cancers [patent_app_type] => utility [patent_app_number] => 16/853230 [patent_app_country] => US [patent_app_date] => 2020-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 6653 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16853230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274645 [patent_doc_number] => 11613576 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Trispecific binding proteins, methods, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/843792 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 77 [patent_no_of_words] => 93858 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 342 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437139 [patent_doc_number] => 20200354465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => Methods Related to Alemtuzumab [patent_app_type] => utility [patent_app_number] => 16/840293 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204920 [patent_doc_number] => 20200237910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => TREATMENT OF ADVANCED HER2 EXPRESSING CANCER [patent_app_type] => utility [patent_app_number] => 16/828045 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420657 [patent_doc_number] => 20200345855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/821535 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16821535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090503 [patent_doc_number] => 20200199238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 16/810744 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090501 [patent_doc_number] => 20200199237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 16/810686 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343625 [patent_doc_number] => 20200308275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => HER3 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/805620 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283777 [patent_doc_number] => 20200277379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => PHARMACEUTICAL COMPOSITION COMBINING IMMUNOLOGIC AND CHEMOTHERAPEUTIC METHOD FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/804733 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19325990 [patent_doc_number] => 12043655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Constitutively active chimeric cytokine receptors [patent_app_type] => utility [patent_app_number] => 16/804917 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 46 [patent_no_of_words] => 22474 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315119 [patent_doc_number] => 11629188 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/803972 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 118 [patent_no_of_words] => 26270 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545335 [patent_doc_number] => 11718675 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy [patent_app_type] => utility [patent_app_number] => 16/803751 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 18360 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803751 [rel_patent_id] =>[rel_patent_doc_number] =>)